Vestal Point Capital LP Acquires New Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Vestal Point Capital LP bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 250,000 shares of the biotechnology company's stock, valued at approximately $30,398,000. Sarepta Therapeutics makes up 1.8% of Vestal Point Capital LP's portfolio, making the stock its 24th largest position. Vestal Point Capital LP owned about 0.26% of Sarepta Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of SRPT. Manchester Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after buying an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 156 shares during the period. Newbridge Financial Services Group Inc. acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $36,000. Steward Partners Investment Advisory LLC grew its stake in shares of Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares during the period. Finally, Smartleaf Asset Management LLC grew its stake in shares of Sarepta Therapeutics by 95.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock worth $54,000 after purchasing an additional 216 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This trade represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company's stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT traded up $0.06 during mid-day trading on Wednesday, reaching $40.05. 8,428,037 shares of the company's stock were exchanged, compared to its average volume of 1,767,439. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock has a market capitalization of $3.94 billion, a PE ratio of 32.04 and a beta of 0.85. The business's fifty day simple moving average is $56.56 and its 200-day simple moving average is $95.81. Sarepta Therapeutics, Inc. has a 52-week low of $34.10 and a 52-week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The business had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. During the same quarter last year, the business posted $0.73 earnings per share. The business's revenue was up 80.2% on a year-over-year basis. On average, equities research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SRPT has been the topic of a number of research analyst reports. Scotiabank dropped their price target on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research note on Thursday, March 20th. Guggenheim reduced their price target on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft reduced their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a report on Wednesday, March 19th. Needham & Company LLC decreased their target price on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Oppenheimer reduced their price target on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $122.61.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.